Qinglin Pei

Qinglin Pei, PhD

Associate Professor

Department: Biobehavioral Nursing Science
Business Phone: (352) 273-6394
Business Email: qlpei@ufl.edu

About Qinglin Pei

My research interests include clinical trials design & analysis, survival analysis, machine learning and Bayesian methodology.

Teaching Profile

Courses Taught
2019-2023
PHC6022 Design and Conduct of Clinical Trials
2016-2017
PHC6050C Biostatistical Methods I

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-6584-4859

Areas of Interest
  • Clinical Trials Design & Analysis
  • Longitudinal Data Analysis
  • Bayesian modeling
  • Machine Learning
  • Survival Analysis

Publications

2024
Accelerating pediatric Hodgkin lymphoma research: the Hodgkin Lymphoma Data Collaboration (NODAL).
Journal of the National Cancer Institute. 116(5):642-646 [DOI] 10.1093/jnci/djae013. [PMID] 38273668.
2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.
JAMA network open. 7(1) [DOI] 10.1001/jamanetworkopen.2023.51062. [PMID] 38241048.
2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children’s Oncology Group study.
British journal of haematology. 201(6):1192-1199 [DOI] 10.1111/bjh.18734. [PMID] 36922022.
2023
Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy.
International journal of radiation oncology, biology, physics. 116(5):1025-1030 [DOI] 10.1016/j.ijrobp.2023.02.020. [PMID] 36868525.
2023
Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children’s Oncology Group AHOD 1331 study.
Journal of patient-reported outcomes. 7(1) [DOI] 10.1186/s41687-023-00653-0. [PMID] 37947987.
2023
Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: A report from the Children’s Oncology Group Study AHOD0831.
Pediatric blood & cancer. 70(8) [DOI] 10.1002/pbc.30452. [PMID] 37243975.
2022
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma.
The New England journal of medicine. 387(18):1649-1660 [DOI] 10.1056/NEJMoa2206660. [PMID] 36322844.
2022
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children’s Oncology Group.
Pediatric blood & cancer. 69(6) [DOI] 10.1002/pbc.29649. [PMID] 35338689.
2022
Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331
Blood. 140(Supplement 1):6565-6566 [DOI] 10.1182/blood-2022-167188.
2022
Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children’s Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma.
International journal of particle therapy. 8(3):55-57 [DOI] 10.14338/IJPT-21-00012.1. [PMID] 35127976.
2022
P086: Advancing Pediatric Hodgkin Lymphoma Research Through NODAL
HemaSphere. 6:39-40 [DOI] 10.1097/01.hs9.0000890912.56229.80.
2022
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group.
International journal of radiation oncology, biology, physics. 112(4):890-900 [DOI] 10.1016/j.ijrobp.2021.10.152. [PMID] 34767937.
2022
Peripheral Neuropathy in Children with High Risk Hodgkin Lymphoma (HL): The Role of Protocol-Stipulated Dose Modification in the Children’s Oncology Group (COG) AHOD1331 Study
Blood. 140(Supplement 1):6550-6551 [DOI] 10.1182/blood-2022-167046.
2022
Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials.
The Lancet. Haematology. 9(1):e49-e57 [DOI] 10.1016/S2352-3026(21)00349-5. [PMID] 34971582.
2022
T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
HemaSphere. 6:40-40 [DOI] 10.1097/01.hs9.0000890916.12776.84.
2022
Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis.
Blood. 140(10):1086-1093 [DOI] 10.1182/blood.2022016098. [PMID] 35763667.
2021
LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.
Leukemia & lymphoma. 62(3):606-613 [DOI] 10.1080/10428194.2020.1839651. [PMID] 33112183.
2021
Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031.
Pediatric blood & cancer. 68(9) [DOI] 10.1002/pbc.29212. [PMID] 34245210.
2021
Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group.
Blood. 137(11):1449-1456 [DOI] 10.1182/blood.2020007225. [PMID] 33512412.
2020
An evaluation of machine learning techniques to predict the outcome of children treated for Hodgkin-Lymphoma on the AHOD0031 trial: A report from the Children’s Oncology Group.
Applied artificial intelligence : AAI. 34(14):1100-1114 [DOI] 10.1080/08839514.2020.1815151. [PMID] 33731974.
2020
Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients.
Melanoma research. 30(1):52-61 [DOI] 10.1097/CMR.0000000000000625. [PMID] 31135600.
2019
Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group.
British journal of haematology. 187(1):39-48 [DOI] 10.1111/bjh.16014. [PMID] 31180135.
2019
Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children’s Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(32):3009-3017 [DOI] 10.1200/JCO.19.00812. [PMID] 31539308.
2018
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, phase 1-2 trial.
The Lancet. Oncology. 19(9):1229-1238 [DOI] 10.1016/S1470-2045(18)30426-1. [PMID] 30122620.
2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children’s Oncology Group study.
Pediatric blood & cancer. 65(7) [DOI] 10.1002/pbc.27034. [PMID] 29528181.
2018
Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children’s Oncology Group.
Pediatric blood & cancer. 65(12) [DOI] 10.1002/pbc.27375. [PMID] 30277639.
2018
Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children’s Oncology Group AHOD0031.
International journal of radiation oncology, biology, physics. 100(5):1119-1125 [DOI] 10.1016/j.ijrobp.2018.01.002. [PMID] 29722656.
2018
Pericardial effusion in Hodgkin lymphoma: a report from the Children’s Oncology Group AHOD0031 protocol.
Blood. 132(11):1208-1211 [DOI] 10.1182/blood-2018-02-834465. [PMID] 30061157.
2018
Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children’s Oncology Group.
Cancer. 124(15):3210-3219 [DOI] 10.1002/cncr.31519. [PMID] 29738613.
2018
Significance of pleural effusion at diagnosis in pediatric Hodgkin lymphoma: a report from Children’s Oncology Group protocol AHOD0031.
Pediatric radiology. 48(12):1736-1744 [DOI] 10.1007/s00247-018-4197-6. [PMID] 30014200.
2018
Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children’s Oncology Group.
Pediatric blood & cancer. 65(1) [DOI] 10.1002/pbc.26753. [PMID] 28802087.
2017
Hospitalization and Rehospitalization in Parkinson Disease Patients: Data From the National Parkinson Foundation Centers of Excellence
PLoS One. 12(7) [DOI] 10.1371/purnal.pone.0180425.
2017
Hospitalization and rehospitalization in Parkinson disease patients: Data from the National Parkinson Foundation Centers of Excellence.
PloS one. 12(7) [DOI] 10.1371/journal.pone.0180425. [PMID] 28683150.
2017
Locomotor Training and Strength and Balance Exercises for Walking Recovery After Stroke: Response to Number of Training Sessions.
Physical therapy. 97(11):1066-1074 [DOI] 10.1093/ptj/pzx079. [PMID] 29077960.
2017
Regional variation in post-stroke multidisciplinary rehabilitation care among veteran residents in community nursing homes.
Journal of multidisciplinary healthcare. 10:75-85 [DOI] 10.2147/JMDH.S123905. [PMID] 28280351.
2016
Applying Triple-Matrix Masking for Privacy Preserving Data Collection and Sharing in HIV Studies.
Current HIV research. 14(2):121-9 [PMID] 26511340.
2016
Concordance and discordance between measured and perceived balance and the effect on gait speed and falls following stroke.
Clinical rehabilitation. 30(3):294-302 [DOI] 10.1177/0269215515578294. [PMID] 25810426.
2016
Poststroke Rehabilitation and Restorative Care Utilization: A Comparison Between VA Community Living Centers and VA-contracted Community Nursing Homes.
Medical care. 54(3):235-42 [DOI] 10.1097/MLR.0000000000000494. [PMID] 26807537.
2016
Sex Differences in the Clinical Progression of Parkinson’s Disease.
Journal of obstetric, gynecologic, and neonatal nursing : JOGNN. 45(5):749-56 [DOI] 10.1016/j.jogn.2016.05.002. [PMID] 27444842.
2016
The Effects of Stroke Type, Locus, and Extent on Long-Term Outcome of Gait Rehabilitation: The LEAPS Experience.
Neurorehabilitation and neural repair. 30(7):615-25 [DOI] 10.1177/1545968315613851. [PMID] 26498434.
2015
Development of a Review-of-Systems Screening Tool for Orthopaedic Physical Therapists: Results From the Optimal Screening for Prediction of Referral and Outcome (OSPRO) Cohort.
The Journal of orthopaedic and sports physical therapy. 45(7):512-26 [DOI] 10.2519/jospt.2015.5900. [PMID] 25996361.
2015
Geriatrics Consults Associated With Improved Mortality and Disposition in Hospitalized Elders
Journal of the American Geriatrics Society. 63(1, SI)
2014
Direct evidence for BBSome-associated intraflagellar transport reveals distinct properties of native mammalian cilia.
Nature communications. 5 [DOI] 10.1038/ncomms6813. [PMID] 25504142.
2014
Recognition and treatment of depressive symptoms in Parkinson’s disease: the NPF dataset.
Journal of Parkinson's disease. 4(4):639-43 [DOI] 10.3233/JPD-140382. [PMID] 25035310.

Grants

Jun 2024 ACTIVE
Testing the Pain Relief of musculOskeletal conditions and Arthritis using Culturally Tailored InterVentions for Black Elders (PROACTIVE) Intervention: A Randomized Controlled Trial
Role: Co-Investigator
Funding: NATL INST OF HLTH NINR
Jul 2023 ACTIVE
Frequent Standardized Oral Care Using Human Milk to Reduce Oral Dysbiosis and Improve Health Outcomes in Preterm Very Low Birth Weight Infants
Role: Co-Investigator
Funding: GERBER FOUNDATION
Mar 2023 ACTIVE
Children's Oncology Group Statistics and Data Center
Role: Project Manager
Funding: UNIV OF SOUTHERN CALIFORNIA via NATL INST OF HLTH NCI
Jul 2022 – Jan 2024
An Integrative Radiogenomic Framework for Predicting Treatment Failure in Adolescents & Young Adults with Hodgkin Lymphoma
Role: Principal Investigator
Funding: EMORY UNIV via US ARMY MED RES ACQUISITION
Apr 2019 – Feb 2023
Children's Oncology Group Statistics and Data Center
Role: Project Manager
Funding: PUBLIC HLTH INST via NATL INST OF HLTH NCI
Mar 2014 – Feb 2019
Children's Oncology Group Statistics and Data Center
Role: Project Manager
Funding: NATL INST OF HLTH NCI

Education

Ph.D. in Statistics (Minor: Genetics)
2013 · University of Wisconsin

Contact Details

Phones:
Business:
(352) 273-6394
Emails:
Business:
qlpei@ufl.edu
Addresses:
Business Mailing:
PO Box 100197
GAINESVILLE FL 32610
Business Street:
1225 CENTER DR
GAINESVILLE FL 32610